A Novel Target Delineation Scheme in High-grade Glioma Patients: a Randomized Single-blind Clinical Trial

The main question it aims to answer are: 1. whether the new target delineation scheme can improve Progression-free Survival 2. whether it can reduce the incidence of radiation complications in high-grade glioma patients. Participants in trial group will be performed radiotherapy of new target delineation method after the completion of the operation within 4-6 weeks., while participants in the control group be performed radiotherapy of EORTC(European organisation for research and treatment of cancer) target delineation method.Temozolomide 75 mg / ( m² · d ) will be given to both groups of patients during radiotherapy. After radiotherapy, its dose changes to 150 \~ 200 mg / ( m² · d ) for 5 days and stopped for 23 days as a cycle. There are 6 cycles in total.

NCT Number	NCT06215495
Lead Sponsor	Zhujiang Hospital
Conditions	Radiation Toxicity, MRI Simulated Positioning, High Grade Glioma, Progression-free Survival, Overall Survival
Enrollment	88 participants
Start Date	2024-02-18
Primary Completion	2027-05-28 (estimated)
Study Completion	2027-06-01 (estimated)
Updated on ClinicalTrials.gov	2024-03-15